Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer

Area of Science:

• Urology
• Oncology
• Pathology

Background:

• Non-muscle-invasive bladder cancer (NMI-BC) is a chronic condition with high recurrence rates (up to 80%) and risk of progression to muscle-invasive disease (up to 45%).
• Current prediction relies on clinicopathologic variables like tumor grade, stage, and CIS, but their reproducibility is limited.
• Molecular markers offer potential for improved prognosis prediction, especially for progression.

Purpose of the Study:

• To evaluate the potential of molecular markers in predicting the clinical outcomes of NMI-BC.
• To address the limitations of clinicopathologic variables in individual prognosis prediction.
• To investigate the role of molecular markers in predicting recurrence and progression in NMI-BC.

Main Methods:

• Analysis of clinicopathologic variables including tumor multiplicity, size, prior recurrence rate, grade, stage, and carcinoma in situ (CIS).
• Exploration of molecular markers, including immunohistochemical markers, gene expression signatures, and molecular grade (FGFR3 mutation status, Ki-67 expression).
• Assessment of the reproducibility of prognostic markers (both clinical and molecular) in NMI-BC.

Main Results:

• Clinicopathologic variables like multiplicity, tumor size, and prior recurrence predict recurrence in pTa NMI-BC.
• Tumor grade, stage, and CIS are key predictors for progression to muscle-invasive bladder cancer (MI-BC).
• Molecular markers show promise for predicting progression, but their clinical utility is currently limited and their reproducibility is understudied.

Conclusions:

• Clinicopathologic factors remain important for predicting NMI-BC outcomes, but their reproducibility is a concern.
• Molecular markers hold significant promise for predicting progression, but further research is needed to validate their clinical utility and reproducibility.
• Addressing the reproducibility of prognostic markers is crucial for advancing the clinical management of NMI-BC.